Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab after chemoradiation in Stage III NSCLC
NCT02768558Phase 3Terminated
- Sponsor
- RTOG Foundation
- Start
- Oct 2016
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by RTOG Foundation. Started Oct 2016; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02768558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02768558.